A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line

NCT04281524 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business decision non-safety related.

Conditions

PICC-associated Thrombosis

Interventions

DRUG: CSL312
DRUG: Placebo

Sponsor

CSL Behring